Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is increasingly prevalent worldwide, and disease‐modifying treatments may soon be at hand; hence, now, more than ever, there is a need to develop techniques that allow earlier and more secure diagnosis. Current biomarker‐based guidelines for AD diagnosis, which have replaced the historical symptom‐based guidelines, rely heavily on neuroimaging and cerebrospinal fluid (CSF) sampling. While these have greatly improved the diagnostic accuracy of AD pathophysiology, they are less practical for application in primary care, population‐based and epidemiological settings, or where resources are limited. In contrast, blood is a more accessible and cost‐effective source of biomarkers in AD. In this review paper, using the recently proposed amyloid, tau and neurodegeneration [AT(N)] criteria as a framework towards a biological definition of AD, we discuss recent advances in biofluid‐based biomarkers, with a particular emphasis on those with potential to be translated into blood‐based biomarkers. We provide an overview of the research conducted both in CSF and in blood to draw conclusions on biomarkers that show promise. Given the evidence collated in this review, plasma neurofilament light chain (N) and phosphorylated tau (p‐tau; T) show particular potential for translation into clinical practice. However, p‐tau requires more comparisons to be conducted between its various epitopes before conclusions can be made as to which one most robustly differentiates AD from non‐AD dementias. Plasma amyloid beta (A) would prove invaluable as an early screening modality, but it requires very precise tests and robust pre‐analytical protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationMicroglia: Active sensor and versatile effector cells in the normal and pathologic brain
Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014
Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
How neuroinflammation contributes to neurodegeneration
Ransohoff, R. M. (2016) · Science · doi:10.1126/science.aag2590 · Cited by 1,967
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
A polarizing question: do M1 and M2 microglia exist?
Ransohoff, R. M. (2016) · Nature Neuroscience · doi:10.1038/nn.4338 · Cited by 1,573
An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455
Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Self-citationInflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., Renbing, X., & Peck, A. (1988) · Annals of Neurology · doi:10.1002/ana.410230206 · Cited by 1,225
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103
Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070
Self-citationTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Self-citationKuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740
Self-citationPlasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Self-citationReduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Lee (2019) · doi:10.1038/s12276-019-0299-y · Cited by 635
Plasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626
Self-citationMielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621
Molecular genetics of early-onset Alzheimer’s disease revisited
Cacace, R., Sleegers, K., & Van Broeckhoven, C. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.012 · Cited by 617
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586
Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.06.2266 · Cited by 585
Hansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0485-0 · Cited by 585
Self-citationPreclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564
A multicentre validation study of the diagnostic value of plasma neurofilament light.
Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23620-z · Cited by 545
Self-citationReiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70228-4 · Cited by 541
Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citationCurrent state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Self-citationBlood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003680 · Cited by 506
Self-citationYKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504
Plasma tau in Alzheimer disease
Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P. S., Andreasson, U., Stomrud, E., Palmqvist, S., Baker, D., Tan Hehir, C. A., Jeromin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003246 · Cited by 502
Self-citationZetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487
Self-citationPlasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study
van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70501-4 · Cited by 458
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15436-0 · Cited by 450
Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435
Self-citationPlasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434
Suárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401
Self-citationPalmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353
Self-citationLantero Rodriguez, J., Karikari, T. K., Suárez-Calvet, M., Troakes, C., King, A., Emersic, A., Aarsland, D., Hye, A., Zetterberg, H., Blennow, K., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02195-x · Cited by 350
Self-citationIncreased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0071-x · Cited by 303
Self-citationCerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort
Schoonenboom, N. S. M., Reesink, F. E., Verwey, N. A., Kester, M. I., Teunissen, C. E., van de Ven, P. M., Pijnenburg, Y. A. L., Blankenstein, M. A., Rozemuller, A. J., Scheltens, P., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31823ed0f0 · Cited by 302
Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253
Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration
Weston, P. S. J., Poole, T., Ryan, N. S., Nair, A., Liang, Y., Macpherson, K., Druyeh, R., Malone, I. B., Ahsan, R. L., Pemberton, H., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004667 · Cited by 245
Self-citationRiemenschneider, M., Wagenpfeil, S., Vanderstichele, H., Otto, M., Wiltfang, J., Kretzschmar, H., Vanmechelen, E., Förstl, H., & Kurz, A. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001220 · Cited by 238
Randall, J., Mörtberg, E., Provuncher, G. K., Fournier, D. R., Duffy, D. C., Rubertsson, S., Blennow, K., Zetterberg, H., & Wilson, D. H. (2013) · Resuscitation · doi:10.1016/j.resuscitation.2012.07.027 · Cited by 230
Self-citationCharacterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076523 · Cited by 209
Self-citationNeurofilament protein in cerebrospinal fluid: A marker of white matter changes
Sjögren, M., Blomberg, M., Jonsson, M., Wahlund, L. ‐., Edman, Å., Lind, K., Rosengren, L., Blennow, K., & Wallin, A. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1242 · Cited by 209
Self-citationCerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
Ashton, N. J., Benedet, A. L., Pascoal, T. A., Karikari, T. K., Lantero-Rodriguez, J., Brum, W. S., Mathotaarachchi, S., Therriault, J., Savard, M., Chamoun, M., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.103836 · Cited by 184
Self-citationAshton, N. J., Leuzy, A., Lim, Y. M., Troakes, C., Hortobágyi, T., Höglund, K., Aarsland, D., Lovestone, S., Schöll, M., Blennow, K., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0649-3 · Cited by 172
Self-citationCombined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0177-6 · Cited by 152
Janelidze, S., Pannee, J., Mikulskis, A., Chiao, P., Zetterberg, H., Blennow, K., & Hansson, O. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2814 · Cited by 147
Dage, J. L., Wennberg, A. M. V., Airey, D. C., Hagen, C. E., Knopman, D. S., Machulda, M. M., Roberts, R. O., Jack, C. R., Petersen, R. C., & Mielke, M. M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.001 · Cited by 145
Karikari, T. K., Emeršič, A., Vrillon, A., Lantero‐Rodriguez, J., Ashton, N. J., Kramberger, M. G., Dumurgier, J., Hourregue, C., Čučnik, S., Brinkmalm, G., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12236 · Cited by 143
Self-citationParnetti, L., Lanari, A., Amici, S., Gallai, V., Vanmechelen, E., & Hulstaert, F. (2001) · Neurological Sciences · doi:10.1007/s100720170055 · Cited by 141
A unifying hypothesis for Alzheimer's disease: from plaques to neurodegeneration
Edwards, F. A. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.03.003 · Cited by 140
Schlaepfer, W., & Lynch, R. (1977) · The Journal of Cell Biology · doi:10.1083/jcb.74.1.241 · Cited by 126
Barthélemy, N. R., Fenaille, F., Hirtz, C., Sergeant, N., Schraen-Maschke, S., Vialaret, J., Buée, L., Gabelle, A., Junot, C., Lehmann, S., et al. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01001 · Cited by 123
O’Connor, A., Karikari, T. K., Poole, T., Ashton, N. J., Lantero Rodriguez, J., Khatun, A., Swift, I., Heslegrave, A. J., Abel, E., Chung, E., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0838-x · Cited by 122
Self-citationImplications of Glycosylation in Alzheimer’s Disease
Haukedal, H., & Freude, K. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.625348 · Cited by 114
Sabbagh, M. N., Lue, L.-F., Fayard, D., & Shi, J. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0069-5 · Cited by 107
Keshavan, A., Pannee, J., Karikari, T. K., Rodriguez, J. L., Ashton, N. J., Nicholas, J. M., Cash, D. M., Coath, W., & Lane, C. A. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-abn.297 · Cited by 94
Self-citationSouthwick, P. C., Yamagata, S. K., Echols, C. L., Higson, G. J., Neynaber, S. A., Parson, R. E., & Munroe, W. A. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66010259.x · Cited by 89
Chhatwal, J. P., Schultz, A. P., Dang, Y., Ostaszewski, B., Liu, L., Yang, H.-S., Johnson, K. A., Sperling, R. A., & Selkoe, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19543-w · Cited by 60
Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline
Mielke, M. M., Aakre, J. A., Algeciras‐Schimnich, A., Proctor, N. K., Machulda, M. M., Eichenlaub, U., Knopman, D. S., Vemuri, P., Graff‐Radford, J., Jack, C. R., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12415 · Cited by 55
Cited by
Pichet Binette, A., Janelidze, S., Cullen, N., Dage, J. L., Bateman, R. J., Zetterberg, H., Blennow, K., Stomrud, E., Mattsson‐Carlgren, N., & Hansson, O. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12787 · Cited by 226
Self-citationCurrent trends in blood biomarker detection and imaging for Alzheimer’s disease
Hu, S., Yang, C., & Luo, H. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114278 · Cited by 84
Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
Kac, P. R., Gonzalez-Ortiz, F., Simrén, J., Dewit, N., Vanmechelen, E., Zetterberg, H., Blennow, K., Ashton, N. J., & Karikari, T. K. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01011-w · Cited by 73
Self-citationPredicting early Alzheimer’s with blood biomarkers and clinical features
AlMansoori, M. E., Jemimah, S., Abuhantash, F., & AlShehhi, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-56489-1 · Cited by 58
Metadata
- Authors
- Alawode, D. O. T., Heslegrave, A. J., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O´Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., Keshavan, A., Snellman, A., Gobom, J., Paterson, R. W., Schott, J. M., Blennow, K., Fox, N. C., & Zetterberg, H.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2021-06-26
- Volume
- 290
- Issue
- 3
- Pages
- 583-601
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W3161967669
- Cited by
- 104
- References
- 80
- FWCI
- 12.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.